Harrow, Inc. (HROW)
(Delayed Data from NSDQ)
$57.48 USD
+1.07 (1.90%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $57.47 -0.01 (-0.02%) 4:54 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.48 USD
+1.07 (1.90%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $57.47 -0.01 (-0.02%) 4:54 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Zacks News
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 48% and 14.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of 37.50% and 2%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for November 14th
by Zacks Equity Research
AKZOY, GTX and HROW have been added to the Zacks Rank #5 (Strong Sell) List on November 14, 2023.
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 4.41% and 2.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?
by Zacks Equity Research
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Harrow Health (HROW) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed at $18.72 in the latest trading session, marking a +1.99% move from the prior day.
Harrow Health (HROW) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed the most recent trading day at $17.91, moving +0.73% from the previous trading session.
Harrow Health (HROW) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed at $18.52 in the latest trading session, marking no change from the prior day.
Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Harrow Health (HROW) closed at $18.68, marking a -1.01% move from the previous day.
Analysts Initiate Coverage: 5 Stocks for Higher Returns
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like MicroStrategy (MSTR), SPX Technologies (SPXC), Cvent (CVT), Harrow Health (HROW) and Banco (BMA).
Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 50% and 0.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 33.33% and 1.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.
Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta
by Zacks Equity Research
Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength That Still Have Upside
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are META, CMG, ACLX, HROW and PRG.
Use New Analyst Coverage to Find Great Momentum Stocks to Buy in May
by Benjamin Rains
One way for investors to find potentially market-beating stocks to buy in May is to search for stocks gaining analyst coverage.
Is HCA Healthcare (HCA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and Harrow Health (HROW) have performed compared to their sector so far this year.
Here's Why Momentum in Harrow (HROW) Should Keep going
by Zacks Equity Research
Harrow (HROW) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed at $25.23 in the latest trading session, marking a -0.63% move from the prior day.
Zacks.com featured highlights Harrow Health and Disc Medicine Opco
by Zacks Equity Research
Harrow Health and Disc Medicine Opco have been highlighted in this Screen of The Week article.
2 Stocks in Focus as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Harrow Health (HROW) and Disc Medicine (IRON).
Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day.